🇺🇸 FDA
Pipeline program

PREDNISONE, BMS-986365, ENZALUTAMIDE, ABIRATERONE, DOCETAXEL, PREDNISOLONE, ABIRATERONE, ENZALUTAMIDE

CA071-1000

Phase 3 small_molecule active

Quick answer

PREDNISONE, BMS-986365, ENZALUTAMIDE, ABIRATERONE, DOCETAXEL, PREDNISOLONE, ABIRATERONE, ENZALUTAMIDE for Metastatic Castration-resistant Prostate Cancer (mCRPC) is a Phase 3 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Celgene Europe Limited
Indication
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials